Barclays’s Annovis Bio ANVS Stock Holding History

Barclays’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$3	–	5243
2025 Q1	$3	Buy	+2	New	+$6	﹤0.01%	5201

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GWM

Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

WFAG

Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's ANVS Position: Q2 2025 in Review

Barclays sold out of Annovis Bio (ANVS) in Q2 2025, closing a stake of 2 shares — an estimated $3 sold.

Barclays first reported a position in ANVS in Q1 2025 and held it in 1 quarter. The position peaked at $3 in Q1 2025. 42 funds tracked by Wall St. Rank hold ANVS as of Q2 2025.

Barclays reported no remaining Annovis Bio position as of Q2 2025 after selling out during the quarter.
Barclays sold 2 Annovis Bio shares in Q2 2025, an estimated $3.
Barclays first reported a position in Annovis Bio in Q1 2025 and held it in 1 quarter.
Barclays's Annovis Bio position peaked at $3 in Q1 2025.
42 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.